Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07154134

Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.

Recruiting

Interested in participating?

Request Info

Key information

Age range

28 week–36 week

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Preterm birth continues to be one of the significant challenges in perinatal medicine because of its high incidence of morbidities and mortalities. Its burden on the infant, the family, healthcare systems, and society is enormous.

Endocan is implicated in the recruitment of circulating lymphocytes to inflammatory sites and leukocyte adhesion and activation. Endocan also inhibits leukocyte-endothelial cell adhesion and reduces the excessive leukocyte recruitment into the lungs.

Copeptin, also known as the arginine vasopressin (AVP) associated glycopeptides. AVP is a vasoactive neurohypophysial hormone. It is one of the primary hormones of the hypothalamic-pituitary-adrenal axis, and its primary function is to regulate water and maintain electrolyte homeostasis. The primary stimulus for AVP release is hyperosmolarity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Prematurity.
  • Gestational age between 28 and 36 weeks.
  • Suffering from respiratory distress syndrome.

Exclusion criteria

  • Intrauterine growth restriction (IUGR).
  • Hypoxic ischemic encephalopathy.
  • Multiple congenital anomalies.
  • Chromosomal abnormalities.
  • Preterm less than 28 weeks.
  • Neonates with a maternal history of chorioamnionitis (early sepsis).
  • Infant of diabetic mother.
  • Prelabor rupture of membranes (PROM)> 2 hours.

Treatment and study plan

Serum endocan

Diagnostic Test

Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.

Serum copeptin

Diagnostic Test

Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.

Primary outcomes

  1. Serum endocan level for prediction of severity of respiratory distress syndrome

    Time frame: First day of life

    Serum endocan level for prediction of severity of respiratory distress syndrome (RDS) will be recorded.

Secondary outcomes

  1. Serum copeptin level for prediction of severity of respiratory distress syndrome

    Time frame: 5th day of life

    Serum copeptin level for the prediction of the severity of respiratory distress syndrome (RDS) will be recorded.

  2. Serum endocan level for prediction of mortality

    Time frame: First day of life

    Serum endocan level for prediction of mortality will be recorded.

  3. Serum copeptin level for prediction of mortality

    Time frame: 5th day of life

    Serum copeptin level for prediction of mortality will be recorded.

Study contacts

Contact information is provided by the study sponsor or research team.

Asmaa M Elmesiry, MD

CONTACT

[email protected]

00201224285567

Sponsors and collaborators

Lead sponsor

Tanta University

Other

Registry information

Official study title

Comparative Study Between Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Sep 4, 2025
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.